Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Stephanie N. Liu"'
Autor:
Stephanie N. Liu, Priya Agarwal, Katja Heinig, Asim Datye, Carolina Sturm‐Pellanda, Andrea Crugnola, Marc Arca, Dale Miles
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 6, Pp 1085-1096 (2023)
Abstract Alectinib, approved as 150 mg capsules for the treatment of adults with advanced ALK‐positive non‐small cell lung cancer, is being assessed in children with ALK‐positive solid and central nervous system tumors. An ad hoc pediatric‐fr
Externí odkaz:
https://doaj.org/article/387720650616442789e21d41ef9614bd
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 1, Pp 40-47 (2020)
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV preexposure prophylaxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by organic
Externí odkaz:
https://doaj.org/article/42017aa69bcb4f1e8e691c66b3c7ceec
Autor:
Dan Lu, Stephanie N. Liu, Michael Z. Liao, Dale Miles, Divya Samineni, Matts Kågedal, Chunze Li
Publikováno v:
Clinical Pharmacology and Therapeutics
Antibody-drug conjugates (ADCs) combine the specificity of an antibody with the cytotoxicity of a chemical agent. They represent a rapidly evolving area of oncology drug development and hold significant promise. There are currently nine ADCs on the m
Autor:
Fjodor Melnikov, Chunze Li, Whitney P. Kirschbrown, Tong Lu, Jin Y. Jin, Eleonora Restuccia, Tanja Badovinac Crnjevic, Z. Machackova, Sandhya Girish, Stephanie N. Liu
Publikováno v:
Journal of Clinical Pharmacology
PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a 420
Autor:
Stephanie N. Liu, Chunze Li
Publikováno v:
Cancer Chemotherapy and Pharmacology
Antibody–drug conjugates (ADCs) are important molecular entities in the treatment of cancer. These conjugates combine the target specificity of monoclonal antibodies with the potent anti-cancer activity of small-molecule therapeutics. The complex s
Autor:
Weize Huang, Junyi Li, Michael Z. Liao, Stephanie N. Liu, Jiajie Yu, Jing Jing, Naoki Kotani, Lynn Kamen, Sebastian Guelman, Dale R. Miles
Publikováno v:
Clinical pharmacology and therapeutics. 112(5)
Adoptive cell therapies (ACTs) have shown transformative efficacy in oncology with five US Food and Drug Administration (FDA) approvals for chimeric antigen receptor (CAR) T-cell therapies in hematological malignancies, and promising activity for T c
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 1, Pp 40-47 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 1, Pp 40-47 (2020)
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV preexposure prophylaxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by organic
Autor:
Zeruesenay Desta, Philip Lazarus, Christy J. W. Watson, Jessica Bo Li Lu, Stephanie N. Liu, Brandon T. Gufford
Publikováno v:
Drug Metab Dispos
Integrase strand transfer inhibitor (INSTI)–based regimens dominate initial human immunodeficiency virus treatment. Most INSTIs are metabolized predominantly via UDP-glucuronosyltransferases (UGTs). For drugs predominantly metabolized by UGTs, incl
Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab
Autor:
Nitzan Sternheim, Marcus Ballinger, Julien Mazieres, Rene Bruno, Benjamin Wu, Stephanie N. Liu, Hina Patel
Publikováno v:
European journal of clinical pharmacology. 77(7)
Autor:
Richard F. Bergstrom, Stephanie N. Liu, Samir K. Gupta, Brandon T. Gufford, Peter L. Anderson, Lane R. Bushman, Jessica Bo Li Lu, Zeruesenay Desta
Publikováno v:
Clin Pharmacol Ther
In a randomized, cross-over study in healthy volunteers (N=14), 2 g probenecid (PRO)-boosted pharmacokinetics of single dose 600 mg tenofovir disoproxil fumarate (TDF) / 400 mg emtricitabine (FTC) (Treatment, T +PRO) was compared with the current On-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c05befe6621a6ccf184b398ac319c5
https://europepmc.org/articles/PMC7703849/
https://europepmc.org/articles/PMC7703849/